Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human leukocyte antigen (HLA) class I molecules are cell surface glycoproteins encoded by genes within the major histocompatibility complex (MHC) on chromosome 6. They play a central role in the adaptive immune system by presenting peptide antigens derived from intracellular proteins to CD8+ cytotoxic T lymphocytes, enabling recognition and elimination of infected or malignant cells. HLA class I molecules are heterodimers composed of a polymorphic heavy (α) chain and a non-polymorphic light chain called β2-microglobulin. The α chain consists of three extracellular domains (α1, α2, and α3), a transmembrane region, and a short cytoplasmic tail. The α1 and α2 domains form the peptide-binding groove. Classical HLA class I molecules (HLA-A, -B, -C) are highly polymorphic, enabling presentation of a wide array of antigenic peptides. Nonclassical class I molecules (e.g., HLA-E, HLA-F, HLA-G) exhibit limited polymorphism and have specialized functions. HLA class I molecules are expressed on nearly all nucleated cells and present endogenous peptides to CD8+ T lymphocytes for immune surveillance and response initiation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Leukocyte Antigen Class I Molecule.